urea and risperidone

urea has been researched along with risperidone in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Anderson, GT; Barido, R; Bonhaus, DW; Brann, MR; Brunmark, P; Davis, RE; Dyssegaard, A; Gardell, LR; Hacksell, U; Johnson, RW; Pounds, L; Tabatabaei, A; Vanover, KE; Veinbergs, I1
Hemrick-Luecke, SK; Hsu, MA; Johnson, BG; Noone, S; Rasmussen, K; Thompson, LK1
Brennan, JA; Comery, TA; Dunlop, J; Ghiron, C; Grauer, SM; Haydar, S; Jow, F; Kelley, C; Marquis, KL; Navarra, RL; Pulicicchio, C; Roncarati, R; Scali, C; Terstappen, GC1
Ball, SR; Bzdega, T; Der, EK; Farago, PR; Hark, TJ; Janczura, KJ; Lavin, KM; Lee, JC; Lee, MJ; Madore, JC; Neale, JH; Olszewski, RT; Profaci, CP1
Elkis, H; Hacksell, U; Meltzer, HY; Peters, P; van Kammen, DP; Vanover, K; Weiner, DM1
Ensom, MHH; Johnson, EG; Johnson, HE; Wilby, KJ1

Reviews

1 review(s) available for urea and risperidone

ArticleYear
Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    The Annals of pharmacotherapy, 2017, Volume: 51, Issue:8

    Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Evidence-Based Medicine; Humans; Olanzapine; Parkinson Disease; Piperazines; Piperidines; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Thiazoles; Urea

2017

Trials

1 trial(s) available for urea and risperidone

ArticleYear
Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.
    Schizophrenia research, 2012, Volume: 141, Issue:2-3

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Female; Follow-Up Studies; Haloperidol; Humans; Male; Middle Aged; Piperidines; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Time Factors; Urea; Young Adult

2012

Other Studies

5 other study(ies) available for urea and risperidone

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 322, Issue:2

    Topics: Amphetamine; Amphetamines; Animals; Antipsychotic Agents; Behavior, Animal; Brain Chemistry; Catalepsy; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Haloperidol; Head Movements; Male; Mice; Mice, Inbred Strains; Motor Activity; Piperidines; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Urea

2007
The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.
    Schizophrenia bulletin, 2007, Volume: 33, Issue:6

    Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Behavior, Animal; Benzodiazepines; Benzoxazoles; Catalepsy; Haloperidol; Intracellular Signaling Peptides and Proteins; Locomotion; Male; Naphthyridines; Neuropeptides; Olanzapine; Orexins; Prolactin; Rats; Rats, Sprague-Dawley; Risperidone; Urea

2007
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
    Psychopharmacology, 2011, Volume: 218, Issue:4

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Avoidance Learning; Cognition Disorders; Drug Evaluation, Preclinical; Drug Interactions; Drug Therapy, Combination; Male; Memory; Mice; Pyridines; Rats; Rats, Long-Evans; Rats, Sprague-Dawley; Receptors, Nicotinic; Risperidone; Schizophrenia; Urea

2011
NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia.
    Translational psychiatry, 2012, Jul-31, Volume: 2

    Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dextroamphetamine; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Exploratory Behavior; Glutamate Carboxypeptidase II; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Recognition, Psychology; Risperidone; Schizophrenia; Soman; Urea

2012